Monkeypox from Congo 1970 to Europe 2022; is there a difference?

Khaity, Abdulrhman; Hasan, Hanan; Albakri, Khaled; Elsayed, Hanaa; Abdelgawad, Hussien Ahmed H.; Islam, Fahadul; Dhawan, Manish; Ghaith, Hazem S.; Emran, Talha Bin

doi:10.1016/j.ijsu.2022.106827

Cited by 9 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such barriers include access, time, self-efficacy, empowerment, and a lack of behavioral control [ 21 ]. Complacency is when the person perceives that the risks of vaccine-preventable diseases are low and vaccination is not deemed a necessary preventive action [ 27 ]. Calculation implies that people attempt to acquire information in order to weigh the risks of infections versus vaccination and make a well-informed decision.…”

Section: Methodsmentioning

confidence: 99%

Monkeypox Vaccine Acceptance among Ghanaians: A Call for Action

et al. 2023

View full text Add to dashboard Cite

A cross-sectional online survey was conducted in Ghana from November to December 2022. Snowball sampling was used to recruit participants via social media platforms, such as WhatsApp, LinkedIn, Telegram, and Facebook. The validated 5C scale was used to assess five psychological factors that influence vaccination behavior and intent: confidence, complacency, constraints, calculation, and collective responsibility. Results: The study drew 605 participants; their mean age was 30.0 ± 6.8; 68.1% were single; 60.8 % were males, and 51.9% were living in Greater Accra (The capital and largest city of Ghana). About 53.9% of the studied Ghanaian population did not intend to receive the MPOX vaccination. Vaccine acceptance among non-healthcare workers (non-HCWs) was significantly lower than among HCWs (41.7 vs. 55.3, p < 0.001). The determinants of vaccine acceptance were male gender (AOR = 1.48, 95% CI, 1.00–2.18, p = 0.049), urban residence (AOR = 0.63, 95% CI, 0.41–0.96, p = 0.033), refusal of coronavirus 2019 vaccine (AOR = 0.29, 95% CI, 0.16–0.52, p < 0.001), confidence in vaccination ((AOR = 2.45, 95% CI, 1.93–3.15, and p < 0.001), and collective responsibility (AOR = 1.34, 95% CI, 1.02–1.75, p = 0.034)). Conclusions: The participants in this study did not show high levels of intention to accept the MPOX vaccination. Consequently, tailoring the efforts aiming to promote MPOX vaccination is needed especially among non-HCWs through increasing their confidence in vaccine effectiveness and safety and promoting the importance of self-vaccination to protect others.

show abstract

Section: Methodsmentioning

confidence: 99%

Monkeypox Vaccine Acceptance among Ghanaians: A Call for Action

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Human infection with monkeypox was first identified in 1970 in the Democratic Republic of Congo [ 15 , 16 ]. Since then, most human cases have occurred in the rainforest regions of West and Central Africa for reasons likely linked to factors of deforestation and climate change, increasing the degree of close contact between humans and animals [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

The global patent landscape of emerging infectious disease monkeypox

Cai,

Zhang,

Zhang

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Background Monkeypox is an emerging infectious disease with confirmed cases and deaths in several parts of the world. In light of this crisis, this study aims to analyze the global knowledge pattern of monkeypox-related patents and explore current trends and future technical directions in the medical development of monkeypox to inform research and policy. Methods A comprehensive study of 1,791 monkeypox-related patents worldwide was conducted using the Derwent patent database by descriptive statistics, social network method and linear regression analysis. Results Since the 21st century, the number of monkeypox-related patents has increased rapidly, accompanied by increases in collaboration between commercial and academic patentees. Enterprises contributed the most in patent quantity, whereas the initial milestone patent was filed by academia. The core developments of technology related to the monkeypox include biological and chemical medicine. The innovations of vaccines and virus testing lack sufficient patent support in portfolios. Conclusions Monkeypox-related therapeutic innovation is geographically limited with strong international intellectual property right barriers though it has increased rapidly in recent years. The transparent licensing of patent knowledge is driven by the merger and acquisition model, and the venture capital, intellectual property and contract research organization model. Currently, the patent thicket phenomenon in the monkeypox field may slow the progress of efforts to combat monkeypox. Enterprises should pay more attention to the sharing of technical knowledge, make full use of drug repurposing strategies, and promote innovation of monkeypox-related technology in hotspots of antivirals (such as tecovirimat, cidofovir, brincidofovir), vaccines (JYNNEOS, ACAM2000), herbal medicine and gene therapy.

show abstract

“…Protein subunit vaccines have an excellent safety profile and can provide good protection when combined with adjuvants for immunization. Another important point is that the 2022 mpox epidemic was concentrated within the homosexual community, which is also vulnerable to a higher prevalence of AIDS (33)(34)(35)(36)(37)(38). The immunodeficiency caused by AIDS can prevent them from being immunized with live attenuated vaccines, which provides a powerful shock to their immune system (39-42), and therefore a recombinant protein vaccine may be a better option for them.…”

Section: Discussionmentioning

confidence: 99%

Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge

et al. 2023

View full text Add to dashboard Cite

Since May 2022, mutant strains of mpox (formerly monkeypox) virus (MPXV) have been rapidly spreading among individuals who have not traveled to endemic areas in multiple locations, including Europe and the United States. Both intracellular and extracellular forms of mpox virus have multiple outer membrane proteins that can stimulate immune response. Here, we investigated the immunogenicity of MPXV structural proteins such as A29L, M1R, A35R, and B6R as a combination vaccine, and the protective effect against the 2022 mpox mutant strain was also evaluated in BALB/c mice. After mixed 15 μg QS-21 adjuvant, all four virus structural proteins were administered subcutaneously to mice. Antibody titers in mouse sera rose sharply after the initial boost, along with an increased capacity of immune cells to produce IFN-γ alongside an elevated level of cellular immunity mediated by Th1 cells. The vaccine-induced neutralizing antibodies significantly inhibited the replication of MPXV in mice and reduced the pathological damage of organs. This study demonstrates the feasibility of a multiple recombinant vaccine for MPXV variant strains.

show abstract

Monkeypox from Congo 1970 to Europe 2022; is there a difference?

Cited by 9 publications

References 5 publications

Monkeypox Vaccine Acceptance among Ghanaians: A Call for Action

Monkeypox Vaccine Acceptance among Ghanaians: A Call for Action

The global patent landscape of emerging infectious disease monkeypox

Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge

Contact Info

Product

Resources

About